Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Abstract
This is a multicenter, double-blind, randomized (in 1:1 ratio) placebo-controlled study to assess the safety and protective efficacy of the subunit recombinant tuberculosis vaccine GamTBvac against the development of respiratory tuberculosis not associated with HIV infection in volunteers aged 18-45 years.
MeSH terms
- Tuberculosis